Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1].

Hetian Lei, Chengchao Shou, Jian Wu, Xiaoying Liu, Luowen He, Meisheng Liu, Qi Guo, Beihai Jiang

Peking University School of Oncology, Beijing Institute for Cancer Research, Beijing 100034, China.

Zhonghua yi xue za zhi 2002 Oct 10

filter terms:

Investigating the bio-activities of peptides selected from phage display peptide library with vascular endothelial growth factor receptor Flt-1. Activities of DHFR-F56/F90 binding to human ubilial vein endothelial cells were detected by immunocytochemistry, and the activity of antiangiogenesis was determined with chick embryo chorioallantoric membrane (CAM) assay. Balb/c nude mice were used as model to detect the activity of DHFR-F56/F90 on inhibiting tumor growth, and immunohistochemistry was employed to determine the localization of the DHFR-F56/F90 in tumor. DHFR-F56/F90 can bind to HUVEC, and DHFR-F56 inhibite angiogenesis in CAM. Meanwhile DHFR-F56 can bind with tumor cells, induce tumor necrosis and inhibit tumor growth in vivo. The peptide F56 is an effective antagonist of VEGF binding to Flt-1 and has a potent utility in antiangiogenesis and inhibiting tumor growth.

Citation

Hetian Lei, Chengchao Shou, Jian Wu, Xiaoying Liu, Luowen He, Meisheng Liu, Qi Guo, Beihai Jiang. Inhibition of tumor growth by a peptide fusion protein binding to vascular endothelial growth factor receptor Flt-1]. Zhonghua yi xue za zhi. 2002 Oct 10;82(19):1342-5